[Leish-l] Leish-l Digest, Vol 41, Issue 5

[Raj]

Hello Professor Shaw and others,
I am writing this from Cellabs Pty Ltd, Sydney Australia. We have successfully developed exo-antigen based antibody detection ELISA . The concept behind the exo-antigen is given under a separate paragraph.    

Our ELISA system  is an indirect one and we use a monoclonal anti-human IgG as an  indicator antibody.  By using this system we have succesfully demonstrated presence of antibodies in serum samples against cutaneous leishmaniases.  I have not published the results as yet but we have done quite a large study involving serum samples from different countries including Brazil. I wanted to include serum samples from Isreal and Indian subcontinent. I am unable to get these samples from these countries. 

Our evaluation included samples from Brazil, Colombia, Panama, Mexico, and Peru. One thing I have observed is that the mucocutaneous condition certainly generates a high titre antibody than other cutaneous conditions.  With this we can conclude that the Th-2 response may be very active during MCL.  On the other hand, some investigator while using our system has observed that the "CL-condition" from Iran did not generate detectable antibodies.  Why it is so  I don't know. We have not been given the samples for re-testing and no clinical data was supplied to us. The way our correspondence went on -  I led to conclude that the  so-called "CL- condition" from Iran may be highly localised one and as yet not received a systemic response. That may be one of the reasons for absence of antibodies in CL samples from Iran. My hyporthesis is that here Th-1 may be in upper hand which might have nullified B-cell response. 
[One has to prove this with immunological evidence]. 
As you know, it is very diffcult for us in Australia to obtain samples from these countries. 

So we have to be careful in generalising the statement. Always there is tendency to state about a condition  " muted B-cell response" during CL condition.   One has to investigate the acutality of this myth. This is my opinion. As Professor Shaw has pointed  out that it is all dependent on the tools and devices we are using for diagnosis of  antibodies against cutaneous form of  leishmania infections. 

My answer went too long for this session.   


Concept behind EXOANTIGEN: These antigens derive from active parasites maintained in serum- free and protein- free condition. These antigens are released due to metabolic activity of the parasites. Dr Samuel Martin of US-Army has conceived this idea.   The concept  of using the exo- antigen is to simulate the system operating within the infected individual where parasites are active and undergoing multiplication and expelling their matabolic products. Concurrently these products are being attacked by the immune system resulting with many immune complexes within the body.

I look forward to hear from other members on this point.

With best wishes

Raj
Dr G-Halli Rajasekariah
Cellabs


----- Original Message ----- 
From: <leish-l-request at lineu.icb.usp.br>
To: <leish-l at lineu.icb.usp.br>
Sent: Wednesday, May 18, 2011 1:00 AM
Subject: Leish-l Digest, Vol 41, Issue 5


> Send Leish-l mailing list submissions to
> leish-l at lineu.icb.usp.br
> 
> To subscribe or unsubscribe via the World Wide Web, visit
> http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l
> or, via email, send a message with subject or body 'help' to
> leish-l-request at lineu.icb.usp.br
> 
> You can reach the person managing the list at
> leish-l-owner at lineu.icb.usp.br
> 
> When replying, please edit your Subject line so it is more specific
> than "Re: Contents of Leish-l digest..."
> 
> 
> Today's Topics:
> 
>   1. CL Antibodies (jeffrey shaw)
> 
> 
> ----------------------------------------------------------------------
> 
> Message: 1
> Date: Mon, 16 May 2011 19:54:58 +0000
> From: jeffrey shaw <jayusp at hotmail.com>
> Subject: [Leish-l] CL Antibodies
> To: Leish-L <leish-l at lineu.icb.usp.br>
> Message-ID: <COL101-W12DEF680383CD45DA37FEDCB8D0 at phx.gbl>
> Content-Type: text/plain; charset="iso-8859-1"
> 
> 
> The accepted idea of no antibodies in cutaneous leishamaniasis is incorrect. They definitely do occur in some but not all cases. However, they may be missed if the wrong antigen is used. The greatest chance of detecting them is to use the homologous antigen.Jeffrey Shaw         
> -------------- next part --------------
> An HTML attachment was scrubbed...
> URL: <http://lineu.icb.usp.br/pipermail/leish-l/attachments/20110516/e701460f/attachment.html>
> 
> ------------------------------
> 
> _______________________________________________
> Leish-l mailing list
> Leish-l at lineu.icb.usp.br
> http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l
> 
> 
> End of Leish-l Digest, Vol 41, Issue 5
> **************************************
> 
> 
> 
> 
> =======
> Email scanned by PC Tools - No viruses or spyware found.
> (Email Guard: 7.0.0.21, Virus/Spyware Database: 6.17530)
> http://www.pctools.com/
> =======



=======
Email scanned by PC Tools - No viruses or spyware found.
(Email Guard: 7.0.0.21, Virus/Spyware Database: 6.17530)
http://www.pctools.com/
=======
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lineu.icb.usp.br/pipermail/leish-l/attachments/20110518/10bb4fce/attachment-0001.htm>